Metformina + Vildagliptina Zentiva K.S.

Metformin Hydrochloride, the active ingredient in Metformina + Vildagliptina Zentiva K.S., is a biguanide presented as an oral tablet for oral use. It is combined with Vildagliptin, a DPP‑4 inhibitor, to improve glycaemic control in adults with type 2 diabetes mellitus, and is indicated for use together with diet and exercise.

GNH USA supplies Metformina + Vildagliptina Zentiva K.S. as a licensed, GDP‑compliant international pharmaceutical supplier, providing quality‑assured products to hospitals, pharmacies and clinics worldwide.

Metformina + Vildagliptina is used in the management of type 2 diabetes mellitus, targeting hyperglycaemia. - Type 2 diabetes mellitus: lowers fasting and post‑prandial glucose levels. - Adjunct to diet and exercise: enhances overall glycaemic management when combined with lifestyle measures. - Overweight patients with type 2 diabetes: contributes to improved insulin sensitivity and metabolic control.

The combination may cause a range of adverse reactions, which are classified by frequency.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort or diarrhoea. - Metallic taste: transient alteration in taste perception. - Headache: mild to moderate headache episodes. - Hypoglycaemia (when combined with other glucose‑lowering agents): mild low blood sugar.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal accumulation of lactate. - Severe hypersensitivity reactions: including skin rash, angio‑edema or anaphylaxis. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain.

Before initiating therapy, several safety considerations should be evaluated. - Renal function: assess eGFR and avoid use in severe renal impairment. - Hepatic impairment: use with caution and monitor liver enzymes. - Risk of lactic acidosis: contraindicated in conditions predisposing to hypoxia. - Pregnancy and lactation: evaluate risk‑benefit ratio before prescribing. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Metformina + Vildagliptina can interact with other medicines, requiring attention to the following categories.

Major Interactions (Avoid): - Insulin or sulfonylureas: increased risk of hypoglycaemia. - Cimetidine: may raise metformin plasma concentrations. - Iodinated contrast agents: can impair renal function and elevate metformin levels.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask symptoms of hypoglycaemia. - Diuretics: can affect renal clearance of metformin. - ACE inhibitors or ARBs: monitor renal function and electrolytes.